Appropriate Test Utilization using Clinical Decision Support Systems
Despite this legal and regulatory structure in the United States, lab testing over utilization is still problematic.
Read MoreScope of Alzheimer’s Disease Testing
Alzheimer’s disease (AD) was first described in 1907 by Aloysius Alzheimer who was caring for patients at a state psychiatric hospital in Frankfurt, Germany. He depicted a patient as having severely impaired memory, trouble with reading and writing, the inability to understand basic questions, and the loss of recognition of everyday objects.
Read MoreTraumatic Brain Injury Testing
The direct and indirect costs of medical diagnosis and treatment, in combination with lost productivity for mild TBI, may be greater than $60 billion annually.
Read MoreThyroid Disease Testing
Thyroid disease is estimated to affect 20 million people in the United States, with up to 60% being undiagnosed.
Read MoreCOVID-19 Testing
As the virus can be transmitted prior to the onset of symptoms, it is best to diagnose patients with COVID-19 prior to symptomatic onset to reduce the spread of the virus.
Read MoreCardiac Biomarkers
It is vital, as new discoveries are made in cardiac biomarkers, that well-designed studies that provide clinical validity and utility are published.
Read MoreBiomarkers in Traumatic Brain Injury
Learn about what’s new in biomarkers for traumatic brain injury in our current blog.
Read MoreMaking Sense of Prostate-Specific Antigen (PSA) Testing
Confusion exists the role of routine PSA testing in screening for prostate cancer. BeaconLBS answers your questions below in our blog about the history, role and evidence regarding routine PSA testing.
Read MoreVitamin D: The “Sunshine” Vitamin: Is testing for Vitamin D necessary?
In recent years, Vitamin D has been a headline in medical news – too much, too little, who is at risk, what about supplements, and is there a link to cancer or heart disease? Read below to learn more about Vitamin D and when to test.
Read More